#Opdivo

FDA Approves Opdivo for Small Cell Lung Cancer

Checkpoint inhibitor extended survival by about three months compared with chemotherapy.

The combination led to improved overall survival compared with chemotherapy.

Cancer-fighting T cells led to complete or partial tumor remission in at least 25% of lung cancer patients.

In a small, early-stage study, the PD-1 checkpoint inhibitor was effective against only some cases of pediatric lymphoma.

A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.

“As far as we know, immunotherapy on its own would not make patients more susceptible to COVID-19."

Efficacy of the combination was investigated in a multicenter, multiple cohort, open-label trial conducted in patients with HCC.

A triple regimen of Opdivo, Yervoy and Cabometyx showed good antitumor activity, but severe side effects were common.

The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.

New site-agnostic therapies highlight the importance of genetic testing.

Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.

Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.

The findings could help identify patients who might benefit from combination therapy with a checkpoint blocker and another inhibitor.

The investigational machine has an 85% accuracy rate.

Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.